An Australian stem cell and regenerative medicine company

April 03, 2020

Cynata Therapeutics (ASX:CYP) 1H20 results & outlook

Finance News Network discusses with Cynata CEO Dr Ross Macdonald the Company’s 1H20 results, upcoming Phase 2 clinical trials, licensing and strategy to build the company's Cymerus cell therapy platform

Read More

January 31, 2020

Feature article in “Clinical Leader” on Cynata’s osteoarthritis program: “Stem Cell Therapy Trial Offers Hope To Osteoarthritis Patients”

Ed Miseta, Clinical Leader’s Chief Editor, discusses Cynata’s osteoarthritis clinical program and general therapeutic stem cell topics with Cynata’s CEO, Dr Ross Macdonald and COO, Dr Kilian Kelly.

Read entire story